{
    "nctId": "NCT00059852",
    "briefTitle": "Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane",
    "officialTitle": "A Phase II Study of OSI-774 (Tarceva) and Gemcitabine for Patients With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 61,
    "primaryOutcomeMeasure": "response rate",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed breast cancer\n\n  * Clinical evidence of metastatic disease\n* Candidate for first- or second-line chemotherapy for metastatic disease\n* Must have received prior anthracycline or taxane therapy (may have had both in the neoadjuvant, adjuvant, or metastatic setting)\n* At least 1 measurable lesion at least 20 mm by CT scan or MRI OR at least 10 mm by spiral CT scan\n\n  * The following are not considered measurable disease:\n\n    * Small lesions less than 20 mm by CT scan or MRI\n    * Bone lesions\n    * Ascites\n    * Pleural/pericardial effusion\n    * Inflammatory breast disease\n    * Lymphangitis cutis/pulmonis\n    * Abdominal masses not confirmed and followed by imaging techniques\n    * Cystic lesions\n* No active CNS metastases (treated CNS metastases stable for more than 8 weeks are allowed)\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Male or female\n\nMenopausal status\n\n* Not specified\n\nPerformance status\n\n* ECOG 0-2\n\nLife expectancy\n\n* At least 3 months\n\nHematopoietic\n\n* Absolute neutrophil count at least 1,500/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n* Hemoglobin at least 8.5 g/dL\n\nHepatic\n\n* Bilirubin no greater than 1.5 times upper limit of normal (ULN)\n* AST no greater than 3 times ULN\n* Alkaline phosphatase no greater than 3 times ULN\n\nRenal\n\n* Creatinine no greater than 1.5 times ULN\n\nCardiovascular\n\n* No symptomatic congestive heart failure\n* No unstable angina pectoris\n* No cardiac arrhythmia\n\nGastrointestinal\n\n* No inability to take oral or nasogastric medication\n* No requirement for IV alimentation\n* No active peptic ulcer disease\n\nOphthalmic\n\n* No abnormalities of the cornea based on history (e.g., dry eye syndrome or Sj\u00f6gren's syndrome)\n* No congenital abnormality (e.g., Fuch's dystrophy)\n* No abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose)\n* No abnormal corneal sensitivity test (Schirmer test or similar tear production test)\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n\n  * Sub-dermal implants and condoms are not considered acceptable forms of contraception\n* No other invasive non-breast malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer\n* No ongoing or active infection\n* No psychiatric illness or social situation that would preclude study compliance\n* No other concurrent uncontrolled illness\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* At least 2 weeks since prior immunotherapy\n* No prior cetuximab\n\nChemotherapy\n\n* At least 2 weeks since prior chemotherapy and recovered\n* No more than 1 prior chemotherapy regimen for metastatic disease\n* No more than 2 prior chemotherapy regimens total, including adjuvant therapy\n\nEndocrine therapy\n\n* Prior hormonal therapy allowed in metastatic and/or adjuvant setting\n\nRadiotherapy\n\n* At least 2 weeks since prior radiotherapy\n* No prior radiotherapy to more than 25% of bone marrow\n* No prior strontium chloride Sr 89\n\nSurgery\n\n* More than 4 weeks since prior major surgery\n* No prior surgical procedures affecting absorption\n\nOther\n\n* No prior epidermal growth factor receptor-targeting therapies (e.g., gefitinib or EKB-569)\n* No concurrent combination antiretroviral therapy for HIV-positive patients\n* No other concurrent antitumor therapy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}